{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:00:43Z","timestamp":1791478843137,"version":"4.3.4"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This phase 2b, randomized, double-blind, placebo-controlled, multiple-dose randomized clinical trial was conducted from August 11, 2021, to September 12, 2022, at 47 centers in the US and 8 in Canada. The study included a 12-week treatment period and a 4-week follow-up period. Key eligibility criteria for participants included age 18 to 70 years; a Psoriasis Area and Severity Index (PASI) score of 12 or greater; a Physician\u2019s Global Assessment score of 3 or greater; and a body surface area covered by plaque psoriasis of 10% or greater. Of 287 patients randomized, 259 (90.2%) received at least 1 dose of study treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04999839?locStr=United%20States&amp;amp;amp;country=United%20States&amp;amp;amp;cond=Plaque%20Psoriasis&amp;amp;amp;intr=placebo&amp;amp;amp;term=NCT04999839&amp;amp;amp;rank=1\">NCT04999839<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.2701","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T18:32:21Z","timestamp":1724265141000},"page":"1066","source":"Crossref","is-referenced-by-count":55,"title":["Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis"],"prefix":"10.1001","volume":"160","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[{"name":"Lynde Institute for Dermatology and Probity Medical Research, Markham, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[{"name":"Innovaderm Research, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"ForCare Medical Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[{"name":"First OC Dermatology Research, Fountain Valley, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha A.","family":"Gangolli","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessamyn","family":"Blau","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Heap","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada"},{"name":"Department of Dermatology, University of Toronto School of Medicine, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi240030r1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","article-title":"Impact of psoriatic disease on quality of life: interim results of a global survey.","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"doi240030r2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"doi240030r3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","article-title":"Psoriasis prevalence and severity by expert elicitation.","volume":"11","author":"Papp","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi240030r4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies.","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"doi240030r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"doi240030r6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"issue":"363","key":"doi240030r7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"doi240030r8","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1038\/s41598-018-25282-2","article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells.","volume":"8","author":"Enerb\u00e4ck","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"doi240030r9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"doi240030r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122271","article-title":"TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.","volume":"10","author":"Diogo","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"doi240030r11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.22631\/rr.2018.69997.1057","article-title":"Association of TYK2 rs34536443 polymorphism with susceptibility to systemic lupus erythematous in the Iranian population.","volume":"3","author":"Faezi","year":"2018","journal-title":"Rheumatology Research"},{"issue":"7422","key":"doi240030r12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"4","key":"doi240030r13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi240030r14","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.133","article-title":"Oral Janus kinase inhibitors in the treatment of atopic dermatitis: a systematic review and meta-analysis.","volume":"3","author":"Lee","year":"2022","journal-title":"Skin Health Dis"},{"issue":"6","key":"doi240030r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis.","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"doi240030r16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review.","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"doi240030r17","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors.","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"doi240030r18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors.","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf"},{"issue":"14","key":"doi240030r19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis.","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"doi240030r20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi240030r21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial.","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"doi240030r24","doi-asserted-by":"publisher","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279.","volume":"66","author":"Leit","year":"2023","journal-title":"J Med Chem"},{"issue":"3","key":"doi240030r25","doi-asserted-by":"publisher","first-page":"AB139","DOI":"10.1016\/j.jaad.2022.06.590","article-title":"33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: results from a phase 1b trial of the novel allosteric TYK2 inhibitor NTX-973.","volume":"87","author":"McElwee","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"doi240030r26","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"doi240030r27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid.","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"3","key":"doi240030r28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi240030r29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000113150","article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.","volume":"216","author":"Revicki","year":"2008","journal-title":"Dermatology"},{"issue":"3","key":"doi240030r30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","article-title":"Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.","volume":"26","author":"Viswanathan","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi240030r31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis.","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi240030r32","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-020-00428-1","article-title":"Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL).","volume":"10","author":"Lacour","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9843","key":"doi240030r33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"doi240030r34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi240030r35","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jid.2022.05.325","article-title":"317 Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858.","volume":"142","author":"Gangolli","year":"2022","journal-title":"J Invest Dermatol"},{"key":"doi240030r22","unstructured":"Armstrong? A, Lebwohl? M, Warren? R, . Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results. Accessed January 8, 2024. https:\/\/acrabstracts.org\/abstract\/deucravacitinib-in-plaque-psoriasis-3-year-safety-and-efficacy-results\/"},{"key":"doi240030r23","unstructured":"Strober? B, Sofen? H, Imafuku? S, . Deucravacitinib in plaque psoriasis: maintenance of response over 3 years in the phase 3 POETYK PSO-1 and PSO-2 trials. Accessed January 8, 2024. https:\/\/eadv.org\/wp-content\/uploads\/scientific-abstracts\/EADV-congress-2023\/Psoriasis.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2822710\/jamadermatology_armstrong_2024_oi_240030_1729089087.32264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:07:31Z","timestamp":1729076851000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2822710"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2701","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}